{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T23:12:28Z","timestamp":1778368348439,"version":"3.51.4"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,3,9]],"date-time":"2024-03-09T00:00:00Z","timestamp":1709942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Celgene and Amgen. Research"},{"name":"National Psoriasis Foundation Summer Student"},{"name":"Jerome L. Greene Foundation Scholar Award"},{"name":"Rheumatology Research Foundation Career Development Funding"},{"name":"Johns Hopkins School of Medicine Biostatistics, Epidemiology and Data Management"},{"DOI":"10.13039\/100007880","name":"Johns Hopkins University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007880","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"Abbvie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To determine characteristics associated with patient-reported treatment success in psoriatic arthritis (PsA).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Rheumatologist-diagnosed PsA patients fulfilling the CASPAR classification were recruited from a single center. PsA outcome measures included: 66\/68 swollen\/tender joint counts, Leeds\/SPARCC dactylitis\/enthesitis indices, psoriasis body surface area (BSA), and patient-reported outcomes (PROs) including PROMIS. The primary outcome was a patient-reported item: \u2018Today, considering the level of control of your psoriatic arthritis and psoriasis, do you consider your treatment has been successful?\u2019. Descriptive and multivariate logistic regression analyses identified clinical predictors of patient-reported treatment success. Patient-reported reasons for lack of treatment success were explored.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 178 participants had a baseline visit. Mean (SD) CASPAR score was 3.7 (0.9), age 51.7 (13.5) years, and BMI 31.3 (7.2)\u00a0kg\/m2. Fifty-two percent were women, and 86.0% white. Treatment success was reported by 116\/178 (65%) patients in the analytic cohort. Among 76 patients who reported treatment failure, the most frequently selected reasons for lack of success were pain (n\u2009=\u200955, 72.4%), fatigue (n\u2009=\u200946, 60.5%), inflamed joints (n\u2009=\u200940, 52.6%) and stiffness (n\u2009=\u200940, 52.6%). Overall, 105 participants had complete data across variables in the logistic regression models. Patient-reported treatment success was independently associated with the 66-swollen\/68-tender joint counts, psoriasis BSA, PROs (pain interference, physical function, fatigue) and TNF-inhibitor therapy, after controlling for BMI and demographics.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Patient-reported treatment success in PsA may be achieved through improvement of inflammatory arthritis, psoriasis, pain, physical function, fatigue and the use of TNF-inhibitors. Patients reported treatment failure was most commonly due to symptoms of pain, fatigue and stiffness.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keae149","type":"journal-article","created":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T23:15:19Z","timestamp":1709939719000},"page":"1111-1121","source":"Crossref","is-referenced-by-count":3,"title":["Characteristics associated with patient-reported treatment success in psoriatic arthritis"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9798-1463","authenticated-orcid":false,"given":"Christeen","family":"Samuel","sequence":"first","affiliation":[{"name":"Johns Hopkins University School of Medicine , Baltimore, MD,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6790-8274","authenticated-orcid":false,"given":"Amanda","family":"Finney","sequence":"additional","affiliation":[{"name":"Biostatistics, Epidemiology, and Data Management (BEAD) Core, Johns Hopkins University School of Medicine , Baltimore, MD,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Grader-Beck","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Rheumatology, Arthritis Center, Psoriatic Arthritis Program, Johns Hopkins University School of Medicine , Baltimore, MD,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5483-8737","authenticated-orcid":false,"given":"Uzma","family":"Haque","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Rheumatology, Arthritis Center, Psoriatic Arthritis Program, Johns Hopkins University School of Medicine , Baltimore, MD,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8438-4413","authenticated-orcid":false,"given":"John","family":"Miller","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Rheumatology, Arthritis Center, Psoriatic Arthritis Program, Johns Hopkins University School of Medicine , Baltimore, MD,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9971-4115","authenticated-orcid":false,"given":"Suzanne M","family":"Grieb","sequence":"additional","affiliation":[{"name":"Patient Research Partner, Johns Hopkins University School of Medicine , Baltimore, MD,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6029-6902","authenticated-orcid":false,"given":"Laura","family":"Prichett","sequence":"additional","affiliation":[{"name":"Biostatistics, Epidemiology, and Data Management (BEAD) Core, Johns Hopkins University School of Medicine , Baltimore, MD,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8644-8567","authenticated-orcid":false,"given":"Ana-Maria","family":"Orbai","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Rheumatology, Arthritis Center, Psoriatic Arthritis Program, Johns Hopkins University School of Medicine , Baltimore, MD,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,3,9]]},"reference":[{"key":"2025030500184925300_keae149-B1","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jaad.2008.09.022","article-title":"The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003\u20132004","volume":"60","author":"Kurd","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"2025030500184925300_keae149-B2","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","article-title":"Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies","volume":"80","author":"Alinaghi","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2025030500184925300_keae149-B3","doi-asserted-by":"crossref","first-page":"108397","DOI":"10.1016\/j.clim.2020.108397","article-title":"Comorbidities associated with psoriatic arthritis: review and update","volume":"214","author":"Perez-Chada","year":"2020","journal-title":"Clin Immunol"},{"key":"2025030500184925300_keae149-B4","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1080\/1744666X.2018.1468252","article-title":"Quality of life in psoriatic arthritis","volume":"14","author":"Gudu","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"2025030500184925300_keae149-B5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","article-title":"Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force","volume":"77","author":"Smolen","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2025030500184925300_keae149-B6","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/ard.2008.102053","article-title":"Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment","volume":"69","author":"Coates","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2025030500184925300_keae149-B7","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1136\/ard.2009.122259","article-title":"Application of the DAREA\/DAPSA score for assessment of disease activity in psoriatic arthritis","volume":"69","author":"Schoels","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2025030500184925300_keae149-B8","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/annrheumdis-2015-207507","article-title":"Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score","volume":"75","author":"Schoels","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2025030500184925300_keae149-B9","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1136\/annrheumdis-2018-214140","article-title":"Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries","volume":"78","author":"Gorlier","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2025030500184925300_keae149-B10","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1111\/1756-185X.13568","article-title":"Factors associated with patient-physician discordance in a prospective cohort of patients with psoriatic arthritis: an Asian perspective","volume":"22","author":"Wang","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"2025030500184925300_keae149-B11","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/acr.24433","article-title":"Measurement of minimal disease activity in psoriatic arthritis using the patient-reported outcomes measurement information system-physical function or the health assessment questionnaire disability index","volume":"74","author":"Chew","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025030500184925300_keae149-B12","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/rheumatology\/kex396","article-title":"Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis","volume":"57","author":"Arnold","year":"2018","journal-title":"Rheumatology"},{"key":"2025030500184925300_keae149-B13","doi-asserted-by":"crossref","first-page":"898","DOI":"10.3899\/jrheum.100857","article-title":"Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study","volume":"38","author":"Cauli","year":"2011","journal-title":"J Rheumatol"},{"key":"2025030500184925300_keae149-B14","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1136\/annrheumdis-2017-211996","article-title":"Validation of the Psoriatic Arthritis Impact of Disease (PsAID) Questionnaire and its potential as a single-item outcome measure in clinical practice","volume":"77","author":"Holland","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2025030500184925300_keae149-B15","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1136\/annrheumdis-2014-205207","article-title":"A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative","volume":"73","author":"Gossec","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2025030500184925300_keae149-B16","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s40744-020-00221-8","article-title":"Disease characteristics and the burden of joint and skin involvement amongst people with psoriatic arthritis: a population survey","volume":"7","author":"Tillett","year":"2020","journal-title":"Rheumatol Ther"},{"key":"2025030500184925300_keae149-B17","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1007\/s13555-022-00770-6","article-title":"Demographic and clinical factors associated with patient-reported remission in psoriatic arthritis","volume":"12","author":"Gondo","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2025030500184925300_keae149-B18","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/acr.24501","article-title":"Identifying minimal and meaningful change in a patient-reported outcomes measurement information system for rheumatoid arthritis: use of multiple methods and perspectives","volume":"74","author":"Bartlett","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025030500184925300_keae149-B19","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s40744-021-00289-w","article-title":"A novel qualitative study assessing patient-reported outcome measures among people living with psoriatic arthritis or ankylosing spondylitis","volume":"8","author":"Chakravarty","year":"2021","journal-title":"Rheumatol Ther"},{"key":"2025030500184925300_keae149-B20","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/acr.21711","article-title":"Obesity and the prediction of minimal disease activity: a prospective study in psoriatic arthritis","volume":"65","author":"Di Minno","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025030500184925300_keae149-B21","doi-asserted-by":"crossref","first-page":"52","DOI":"10.4081\/reumatismo.2020.1266","article-title":"Remission, low disease activity and improvement of pain and function in psoriatic arthritis patients treated with IL-12\/23 and IL-17 inhibitors. A multicenter prospective study","volume":"72","author":"Perrotta","year":"2020","journal-title":"Reumatismo"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae149\/57210132\/keae149.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/3\/1111\/57210132\/keae149.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/3\/1111\/57210132\/keae149.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:22:11Z","timestamp":1741134131000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/3\/1111\/7625110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,9]]},"references-count":21,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3,9]]},"published-print":{"date-parts":[[2025,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae149","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2024,3,9]]}}}